Rezolute, Inc.
RZLT · XNASCIK 1509261fmd_08GNKK1XEB8YK3Q14Y4VAMZYNGManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Mar 24, 2010 to Sep 30, 2026, 63 periods
| Line item | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | 12 | 17 | 19 | 14 | 15 | 32 | 44 | 56 | 62 | 54 |
| Total operating expenses | 20 | 29 | 26 | 21 | 23 | 42 | 56 | 70 | 80 | 83 |
| Operating income | (20) | (29) | (26) | (21) | (23) | (42) | (56) | (70) | (80) | (83) |
| Interest expense | 0 | 1 | 5 | 0 | 0 | – | – | – | – | – |
| Interest and investment income | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 5 | 5 | 5 |
| Other non-operating income (expense) | 0 | (1) | (5) | 0 | 2 | 1 | 4 | 2 | 5 | – |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | (20) | (30) | (30) | (20) | (21) | (41) | (52) | (68) | (74) | (78) |
| Net income to common shareholders | (24) | (30) | (33) | (20) | (21) | (41) | (52) | (68) | (74) | (78) |